timothy sykes logo
BioMarin Acquires Amicus for $4.8 Billion, Sparking Surge in Stocks Thumbnail
ADD US ONG Google News

BioMarin Acquires Amicus for $4.8 Billion, Sparking Surge in Stocks

BRYCE TUOHEY•UPDATED DEC. 21, 2025, 8:13 AM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

Amicus Therapeutics Inc. stocks have been trading up by 30.03 percent amid recent FDA designations boosting investor confidence.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: <> is currently operating with strong gross margins of 89.8%, keeping contrast to its negative profitability ratios, including a pretax profit margin at -35.5%. While revenues have shown robust growth, achieving a 22.8% increase over three years, the company’s valuation measures illustrate potential overvaluation; a price-to-sales ratio of 7.31 and a price-to-book ratio of 18.99 suggest high market expectations not yet matched by performance metrics. Financially, the company’s balance sheet presents vulnerabilities, evidenced by a high total debt to equity ratio of 1.92 and a return on equity at an unsettling -75.59%. These figures suggest that the company’s operating results are being curtailed by external debt, hindering its potential to leverage strong revenue into optimized profitability.

  2. Technical Analysis & Trading Strategy: Recent weekly price patterns indicate heightened volatility, with a significant surge to $14.16 following a period of trading in a narrow range around $10.72 to $11. The sharp uptick coincided with the BioMarin acquisition announcement, establishing a new support level at $14.16. From a technical standpoint, the dominant trend is bullish, with strong buying signals evident in the surging volumes and price levels surpassing recent resistance. Traders might capitalize on this momentum by considering long positions, setting initial stop-loss orders just below the $14.16 support to mitigate downside risks. Market participants should be cautious of potential pullbacks to around $11 should any unforeseen developments arise.

  3. Catalysts & Outlook: The key catalyst driving <>’s recent price surge is the announced acquisition by BioMarin Pharmaceutical at $14.50 per share. The deal presents a substantial premium over the pre-announcement price, effectively pushing shares up by over 30%. Analysts, such as Citi’s Samantha Semenkow, remain optimistic for <>’s rare disease therapy pipeline, with projected sales of over $1 billion by 2028. Coupled with analyst ratings and a positive market reception, <>’s outlook appears favorable. It aligns well with broader biotechnology sector dynamics, particularly concerning expansion and specialty focus. Resistance and support levels at $14.50 and $14.16, respectively, provide tactical benchmarks for monitoring as market activities unfold and the acquisition finalizes.

Candlestick Chart

Weekly Update Dec 15 – Dec 19, 2025: On Sunday, December 21, 2025 Amicus Therapeutics Inc. stock [NASDAQ: FOLD] is trending up by 30.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

FOLD’s charts reflect a remarkable uptick, closing at $14.16 from a prior standing of $10.91 just a day before the BioMarin announcement. The intraday increase in value further testifies to investor optimism surrounding this transaction. The recently disclosed earnings report highlights a revenue stream of $528.3M, augmented by a resilient gross margin of 89.8%. Despite the excellent gross margin, overall profitability seems stifled with a profit margin showing a deficit of -2.35%. A robust current ratio of three signifies sound liquidity, while revenue growth marks an optimistic trajectory.

More Breaking News

Major financial indicators spotlight potential in Amicus’s growth strategy, although its price-to-book ratio and debt to equity remain notably high. However, the positive market reaction manifestly boosts stockholder morale, reflective of strategic optimism regarding future earnings amplified by the acquisition.

Conclusion

As the acquisition story unfolds, the transformative potential of this deal reverberates through the financial markets. The 30% rise in stock price encapsulates trader confidence in BioMarin’s strategic foresight and Amicus’s therapeutic prospects. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This sentiment is reflected in the cautious optimism despite legal investigations that cast a shadow on immediate proceedings. The overarching acquisition narrative underscores a landmark move in biotech consolidation, loaded with possibilities for future financial growth and strategic synergy. In essence, the completion of this acquisition could well recalibrate the competitive landscape, yielding lasting impacts for stakeholders within the therapeutic segments concerned.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading FOLD

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”